ArticleJournal of translational medicine2025
DrugBERT: a BERT-based approach integrating LDA topic embedding and efficacy-aware mechanism for predicting anti-tumor drug efficacy.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDue to the complexity of tumor genetic heterogeneity, personalized medicine has progressively emerged as the central focus of cancer research. However, how to accurately predict the drug response of patients before receiving treatment is the critical challenge to the development of this field.
methodsThis paper proposes DrugBERT, a BERT-based framework integrated with LDA topic embedding and a drug efficacy-aware mechanism for predicting the efficacy of antitumor drugs. The method incorporates LDA-generated topic embedding as a semantic enhancement module into the BERT language model and introduces a drug efficacy-aware attention mechanism to prioritize drug efficacy-related semantic features. The model is via LSTM to capture long-range dependencies in clinical text data. In addition, the SMOTE algorithm is used to synthesize samples of the minority class to solve the problem of data imbalance.
resultsThe proposed method DrugBERT demonstrated remarkable performance on a dataset of 958 patients with non-small cell cancer treated with antitumor drugs. Furthermore, when validated on an independent dataset of 266 bowel cancer patients, the model achieved a 3% improvement in AUC over previous methods, signifying its robust generalization capability.
conclusionsDrugBERT can help predict the efficacy of antitumor drugs based on clinical text while exhibiting strong generalization capability. These findings highlight its potential for optimizing personalized therapeutic strategies through language model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.